Related Experiment Video
Updated: Oct 21, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
[131I]metaiodobenzylguanidine therapy in medullary thyroid cancer: Guy's Hospital experience
1Department of Nuclear Medicine, Guy's Hospital, London, United Kingdom.
Abstract:
[131I]Metaiodobenzylguanidine (131I-MIBG) was utilized in the therapy of seven patients with medullary thyroid cancer. Treatment doses ranged from 3.7 to 11 GBq, for upto four total treatments. Six of the seven patients treated showed some response to treatment (from transient partial response to symptom palliation). Treatment was tolerated well in all patients, with minimal side-effects and no signs of hematologic radiotoxicity. These encouraging results emphasize the potential of 131I-MIBG as a form of targetted radiometabolic therapy in patients with medullary thyroid cancer.
Related Concept Videos
Imaging Studies III: Computed Tomography
Goiter

